|Description||Reslizumab is a humanized monoclonal antibody resistant to interleukin-5 (IL-5). It is approved for additional maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.|
|Brife Description||humanized monoclonal antibody, IL-5, asthma|
|Application||the treatment of severe asthma|
Apilimod is a potent and orally bioavailable inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain au...
PD 0220245 is a non-peptide interleukine 8 (IL-8) receptor antagonist.
CK-119, a dihydropyridazino-pyridazine compound, is a potent IL-1 blocker to inhibit cell growth of fibroblast-like corneal and conjunctival cells mainly throug...
SU 5201 is an inhibitor of IL-2 production.
CK 17 is a interleukin-1 antagonist. It can suppress fibroblast proliferation.
Veledimex racemate is the racemate of veledimex. Veledimex is an orally active small molecule diacylhydrazine and controls the expression of the target gene.
IL5 receptor antagonist
Pentagalloylglucose, a polyphenol isolated from the fruits of Pistacia lentiscus, increases a population of Treg cells in conjunction with Treg-inducing factors...